The team will develop a platform using phage display libraries to identify antibody variants specific to targeted tissues, enhancing the development of biologics for immune-oncology, autoimmunity, and other diseases through in vivo screening and next-generation sequencing.
Dr. Lauren Williamson is a translational immunologist specializing in the development of next-generation antibody therapeutics for infectious diseases, cancer, and autoimmunity. At Vanderbilt, she leads initiatives in antibody discovery and engineering, with a focus on monoclonal and bispecific formats. Her research has contributed to the advancement of candidate therapeutics targeting Zika virus, Ebola virus, encephalitic alphaviruses, and other high-impact pathogens.
In addition to her academic work, Dr. Williamson is the founder of TissueAb, an innovative in vivo screening platform designed to identify tissue-targeting antibodies with broad applications in targeted delivery. Supported by Vanderbilt’s Innovation Catalyst Fund, TissueAb exemplifies Dr. Williamson’s commitment to translating immunological breakthroughs into real-world therapeutic solutions.